COVID-19 Project Team: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 22: | Line 22: | ||
*[[User:Sara Zand|Sara Zand, M.D.]] | *[[User:Sara Zand|Sara Zand, M.D.]] | ||
*[[User:Syed rizvi|Syed Rizvi, M.B.B.S.]] | *[[User:Syed rizvi|Syed Rizvi, M.B.B.S.]] | ||
*[[ | *[[User:TayyabaAli|Tayyaba Ali, M.D.]] | ||
'''Dermatologic Disorders of COVID-19 Team Members''' | '''Dermatologic Disorders of COVID-19 Team Members''' | ||
| Line 48: | Line 48: | ||
'''Gastrointestinal disorders and COVID-19''' | '''Gastrointestinal disorders and COVID-19''' | ||
*'''[[User:Farima Kahe|Farima Kahe, M.D.]]''' | *'''[[User:Farima Kahe|Farima Kahe, M.D.]]''' | ||
*[[ | *[[User:TayyabaAli|Tayyaba Ali, M.D.]] | ||
* [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]] | * [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]] | ||
| Line 85: | Line 85: | ||
*'''[[User:Tayyaba Ali|Tayyaba Ali, M.D.]]''' | *'''[[User:Tayyaba Ali|Tayyaba Ali, M.D.]]''' | ||
'''Infectious diseases and COVID-19''' | '''Infectious diseases and COVID-19''' | ||
* [[User:Zaida Obeidat|User:Zaida Obeidat, M.D.]] | * [[User:Zaida Obeidat|User:Zaida Obeidat, M.D.]] | ||
'''[[COVID-19 medical therapy]] | '''[[COVID-19 medical therapy]] | ||
Revision as of 21:32, 12 August 2020
| COVID-19 Project |
|---|
| Introduction |
| Team |
| Meetings' Summary |
| Topics |
| Ongoing Clinical Trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]